Baseline Characteristics of 167 Patients Randomly Assigned to Either Placebo or Extended-Release Niacin Allen J. Taylor et al. Circulation 2004; 110: 3512-3517.

Slides:



Advertisements
Similar presentations
Slide Source: Lipid and Lipoprotein Parameters at Baseline and Drug Treatment: METEOR Trial Baseline, Mean (SD) Time-Weighted Average.
Advertisements

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Lindsay and Choudhury, Nature Reviews: Drug Discovery 2008, 7: Imaging the vessel wall in atherosclerosis.
Enrollment and Outcomes J.J.P. Kastelein, et al. N Engl J Med 2008;358:1431.
Philip J. Barter, et al. Circulation 2011;124:
Monitoring CAC and IMT: A useful clinical tool? Cardiology Service Walter Reed Army Medical Center Walter Reed Army Health Care System NO CONFLICTS TO.
Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 2 ARBITER-2 Trial Presented at The American Heart Association Scientific.
Patient disposition Dichtl W, et al. Am J Cardiol. 2008;102:743-8 AVR = aortic valve replacement; MDCT = multidetector computed tomographic.
Baseline Prevalence of Metabolic Syndrome and Individual Components Among 4258 Older Adults Dariush Mozaffarian, et al. Arch Intern Med. 2008;168:
Baseline Patient Characteristics Bart A.N. Verhoeven, et al. Stroke 2006;37:
Baseline Characteristics of the Patient Population (n=525) Colin Berry, et al. Circulation 2007;115:
Trial profile Prakash Deedwania, et al. Lancet 2006; 368:
Charlotte Kragelund et al N Engl J Med 2005;352: Baseline Clinical Characteristics According to Quartiles of NT-pro-BNP.
DIABETES INSTITUTE JOURNAL CLUB CARINA SIGNORI, D.O., M.P.H. DECEMBER 15, 2011 Atherothrombosis intervention in metabolic syndrome with low HDL/High Triglycerides:
Search strategy and results Amir Kashani, et al. Circulation. 2006;114:
Christopher P. Cannon, M. D. , Eugene Braunwald, M. D. , Carolyn H
Figure 2. Effect of Siberian and Panax ginseng respectively on postprandial glucose level before and after three months of intake in patients with type.
Arch Intern Med. 2004;164(7): doi: /archinte Figure Legend:
Flowchart of participants
Copyright © 2002 American Medical Association. All rights reserved.
Comparison of baseline characteristics in participants who subsequently had an incident cardiovascular event or new-onset diabetes in the Prospective.
From: United Kingdom Prospective Diabetes Study 17: A 9-Year Update of a Randomized, Controlled Trial on the Effect of Improved Metabolic Control on Complications.
MM McDermott and coauthors
AIM HIGH Niacin plus Statin to prevent vascular events
Design of a multicohort evaluation of statin adherence after the start of 2 cost-sharing policies Sebastian Schneeweiss, et al. Circulation 2007;115:
First time a CETP inhibitor shows reduction of serious CV events
AIM-HIGH Niacin Plus Statin to Prevent Vascular Events
Oxford Niacin Trial.
FATS- Familial Atherosclerosis Treatment Study
The ASSERT Study.
Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:
Clinical Trials in Residual Cardiovascular Risk: A Fresh Perspective
Change in mean LVMI with erythropoietin alpha hemoglobin maintenance treatment and control/delayed treatment from baseline to 24 months End point Hemoglobin.
Diabetes hazard rates by number of visits with reported statin use.
Panelists. Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?
End point Fenoldopam, n (%) Dopamine, n (%) p
Efficacy and safety of niacin/laropiprant
Subject Characteristics
Dandan Wang et al. BTS 2018;3: Down-Regulation of miR-24 in Response to Insulin Infusion in Human Plasma Human plasma insulin (A), glucose (B),
Baseline characteristics of CACTI type 1 diabetic subjects with cystatin C measurements (n=509), stratified by CAC progression status Maahs DM et al.
Baseline Characteristics
Kaplan–Meier estimates of the incidence of first heart failure hospitalization during follow-up according to the statin category among patients with type.
Baseline Characteristics, Values at 24-Month Follow-up, and Changes from Baseline* - Part I John J.P. Kastelein, et al. N Engl J Med 2007;356: online.
Baseline Characteristics of the Subjects
Study Participant Flow
Flow Diagram of the Trial Selection Process
Baseline Patients with coronary artery disease (CAD) and high (n=98) versus normal (n=1512) high-density lipoprotein (HDL) levels Doreen DeFaria Yeh, et.
RUTHERFORD-2 Trial design: Patients with heterogeneous familial hypercholesterolemia (HeFH) on statins were randomized in a 2:2:1:1 fashion to subcutaneous.
Baseline characteristics for patients with diabetes in ASCOT-LLA Part I P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157.
Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.
Correlation between plasma C reactive protein (CRP) and angiopoietin-like protein 4 (ANGPTL4). Correlation between plasma C reactive protein (CRP) and.
Baseline Characteristics by hs-CRP
Characteristics of SIRCA Participants
RADIANCE 2 Study: Trial profile
(A) Absolute and (B) change from baseline in 6 min walk distance over time for all patients and by Down syndrome status. (A) Absolute and (B) change from.
Statin Selection in Patients With Pre-Diabetes: Case Considerations
T2DM patients with HF may benefit from SGLT2 inhibitor therapy
Statin Therapy in Patients With Insulin Resistance
Baseline Clinical Characteristics of All Patients and Patients Grouped by Statin Therapy - Part I H. Fukuta et al. Circulation 2005;112:
Baseline demographics and clinical characteristics of 3,956 rosuvastatin-treated patients Donald G. Vidt, et al. Am J Cardiol 2006;97:1602–1606.
Baseline characteristics of study population
Mean fasting C-peptide levels (for all subjects [A]) and mean peak C-peptide levels (all subjects [B], adolescents [C], and adults [D])after mixed-meal.
Flow diagram illustrating diabetes outcomes in the randomly assigned treatment of folic acid and vitamins B6 and B12 of the WAFACS. A total of 1,190 participants.
Enrollment, outcomes, and pharmacokinetics.
Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.
Effect of methylprednisolone versus placebo on the risk of acute kidney injury in a subsample of patients with serial postoperative serum creatinine assessments.
A 63-year-old female with lung adenocarcinoma treated with nivolumab, who experienced pseudoprogression. A 63-year-old female with lung adenocarcinoma.
Section 6: Update on lipid treatment guidelines
Changes in urinary albumin excretion rate in relation to baseline (top), cross-sectional values of GFR (middle), and MABP (bottom) during treatment with.
 Study protocol.  Study protocol. (A) Patients were randomly allocated to placebo or amitriptyline treatment for four weeks. At the end of the month there.
Presentation transcript:

Baseline Characteristics of 167 Patients Randomly Assigned to Either Placebo or Extended-Release Niacin Allen J. Taylor et al. Circulation 2004; 110: 3512-3517

Comparison of Baseline and 12-Mo Serologic Results for Patients Completing the Study Who Were Randomly Assigned to Either Placebo or Extended-Release Niacin Allen J. Taylor et al. Circulation 2004; 110: 3512-3517

Serial HDL-C during the 12-month study period for subjects in the placebo and extended-release niacin groups Allen J. Taylor et al. Circulation 2004; 110: 3512-3517

Serial mean CIMT measurements from the far wall of the bilateral common carotid arteries at baseline and 12 months during treatment with either placebo or extended-release niacin (Niaspan) added to stable statin therapy Allen J. Taylor et al. Circulation 2004; 110: 3512-3517

Change in IMT across 12 months in patients treated with placebo and extended-release niacin in presence or absence of metabolic syndrome or type 2 diabetes mellitus Allen J. Taylor et al. Circulation 2004; 110: 3512-3517